Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) was downgraded to Neutral from Buy at Roth Capital. Allergan Inc. …
The shares of Alexza Pharmaceuticals, Inc (NASDAQ:ALXA) rose more than 23% to $2.80 per share after announcing the Grupo Ferrer Internacional, S.A. agreed to acquire 2 million of its common stock for $4.00 per share.
Earnings, however, missed expectations. Alexza Pharmaceuticals Inc. (ALXA) said it initiated a 10-for-1 reverse stock split of its outstanding shares in an effort to regain compliance with Nasdaq and stay listed on the exchange. Career …
Biovail also recently struck a deal with Alexza Pharmaceuticals ALXA.O to develop and commercialize its inhaled treatment for agitation. Shares of Biovail were up 21 Canadian cents at C$15.58 on the Toronto Stock Exchange on …
Alexza Pharmaceuticals Inc. (ALXA), which develops treatments for conditions affecting the central nervous system, said it plans to offer as much as $40 million in mixed securities, which may include stock. Shares were off 3.3% to $4.15 …
Alexza Pharmaceuticals (NASDAQ: ALXA) shares surged 16.70% to $2.65. Ferrer purchased $8 million of Alexza common stock through new investment and elimination of potential milestone payments. NQ Mobile (NYSE: NQ) …
BOSTON, March 26 (Reuters) - Alexza Pharmaceuticals Inc. ALXA.O reported positive clinical trial results for two of its experimental drugs on Monday, sending its shares soaring more than 48 percent. The Palo Alto, California-based …
[ID:nBNG230203] ALEXZA PHARMACEUTICALS INC ALXA.O, $2.23, down 23.2 pct The company said preliminary ... on the Dow component with an“underweight” rating, saying its stock looked expensive on capital metrics against its global …